Shorter chemo shows promise for HIV patients with lymphoma
NCT ID NCT00006436
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a shorter course of a chemotherapy combination called EPOCH-R in 68 people with HIV and a type of lymphoma. The goal was to see if reducing the amount of chemotherapy could still control the cancer while causing less damage to the immune system. Participants received treatment every 3 weeks for 3 to 6 cycles, and their response was monitored with scans and blood tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab)
What this could lead to
If successful, this approach could offer a shorter, less immune-damaging chemotherapy regimen for people with HIV and lymphoma, potentially reducing infections and future cancer risks.
What could go wrong
This is a small, completed phase 2 trial with no control group, so results are preliminary. The combination still carries significant toxicity risks, and long-term outcomes are uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States